Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranju Baral

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Vaccine|July 30, 2021
Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisionsRachel S Laufer, Amanda J Driscoll, Ranju Baral, et al.
Vaccine|July 8, 2023
Value profile for respiratory syncytial virus vaccines and monoclonal antibodiesJessica A Fleming, Ranju Baral, Deborah Higgins, et al.
JAMA|December 28, 2016
US Spending on Personal Health Care and Public Health, 1996-2013Joseph L Dieleman, Ranju Baral, Maxwell Birger, et al.
The Lancet. Global Health|November 6, 2025
The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementationFarina L Shaaban, Rosalie W Groenendijk, Ranju Baral, et al.
The Lancet. Infectious Diseases|August 11, 2022
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeNatalie I Mazur, Jonne Terstappen, Ranju Baral, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Vaccine|July 30, 2021
Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisionsRachel S Laufer, Amanda J Driscoll, Ranju Baral, et al.
Vaccine|July 8, 2023
Value profile for respiratory syncytial virus vaccines and monoclonal antibodiesJessica A Fleming, Ranju Baral, Deborah Higgins, et al.
JAMA|December 28, 2016
US Spending on Personal Health Care and Public Health, 1996-2013Joseph L Dieleman, Ranju Baral, Maxwell Birger, et al.
The Lancet. Global Health|November 6, 2025
The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementationFarina L Shaaban, Rosalie W Groenendijk, Ranju Baral, et al.
The Lancet. Infectious Diseases|August 11, 2022
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeNatalie I Mazur, Jonne Terstappen, Ranju Baral, et al.
Pageof 5